Q BioMed Inc (OTCQB:QBIO) has named seasoned pharmaceutical and biotechnology professional Kristin Keller its new Chief Commercial Officer, handing her the reins to the global commercialization effort of its metastatic bone pain treatment, Strontium89.
Keller has worked for more than two decades as a marketer and strategist for global pharmaceutical, biotechnology and medical device companies, and she brings extensive experience in the specialty and orphan drug space.
She’s spent time at biotechs including Actelion, Raptor, Alexion and Biomarin, as well as larger pharmaceutical companies such as Novartis, Sanofi, AstraZeneca and Roche.
"We are very excited to welcome Kristin to Q BioMed,” CEO Denis Corin said in a statement. “Her leadership and experience launching medicines will be vital as we commercialize Strontium89 for patients across the globe. We look forward to reaching key milestones in our oncology and rare disease pipeline this year and beyond, while we build out our scientific and commercial capabilities as a sustainable, global biotech company."
In addition to leading the charge for Strontium89, Keller will also contribute strategic insight and direction to the company’s earlier-stage assets.
"The people at Q BioMed share a passion for the patients they serve and a commitment to finding new ways to treat traditionally underserved populations," Keller said. "I look forward to joining the team and building a commercial organization focused on bringing important therapies to patients with cancer and rare disorders."
Strontium89 won approval from the US Food and Drug Administration in November 2019. Q Biomed completed its first commercial production run and shipment in February and has initiated distribution in the US. Distribution to the EU and elsewhere is expected later this year.
The drug, which can be administered every three months, was shown in numerous clinical trials to relieve pain in over 70% of patients who received the treatment, the company said, making it an effective alternative to opioids.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel